open access

Vol 12, No 6 (2017)
Report
Published online: 2017-12-29
Get Citation

Electrotherapy, intervention, therapy... Snapshots from the Congress of the European Society of Cardiology in Barcelona, August 26–30, 2017

Łukasz Figiel, Jarosław D. Kasprzak
DOI: 10.5603/FC.2017.0118
·
Folia Cardiologica 2017;12(6):625-628.

open access

Vol 12, No 6 (2017)
Report
Published online: 2017-12-29

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Electrotherapy, intervention, therapy... Snapshots from the Congress of the European Society of Cardiology in Barcelona, August 26–30, 2017

Journal

Folia Cardiologica

Issue

Vol 12, No 6 (2017)

Pages

625-628

Published online

2017-12-29

DOI

10.5603/FC.2017.0118

Bibliographic record

Folia Cardiologica 2017;12(6):625-628.

Authors

Łukasz Figiel
Jarosław D. Kasprzak

References (5)
  1. Escaned J, Collet C, Ryan N, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J. 2017; 38(42): 3124–3134.
  2. Marrouche NF, Brachmann J, on behalf of CASTLE-AF Investigators. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation: The CASTLE-AF trial. European Society of Cardiology 2017 Congress. August 27, 2017, Barcelona, Spain.
  3. Ezekowitz MD, Pollack CV, Sanders P, et al. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. Am Heart J. 2016; 179: 59–68.
  4. Cannon CP, Bhatt DL, Oldgren J, et al. RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377(16): 1513–1524.
  5. Townsend RR, Mahfoud F, Kandzari D, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017; 390(10108): 2160–2170.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl